News

Prelude Therapeutics Incorporated (Prelude) announced a clinical trial collaboration with BeiGene, for future evaluation of its investigational CDK9 inhibitor, PRT2527, in combination…
Read More...

Immunoprecise Antibodies Ltd. announced that Talem Therapeutics LLC, an independently operating subsidiary of IPA, and Libera Bio S.L., have signed a collaboration agreement to jointly…
Read More...

UCB, a global biopharmaceutical company, and Aitia, a leader in the application of Causal AI and “Digital Twins” to discover and develop new drugs, announced an early drug discovery…
Read More...

GSK plc announced that the China National Medical Products Administration has accepted for review a new drug application for Nucala (mepolizumab) as an add-on maintenance treatment for…
Read More...

AcelRx Pharmaceuticals, Inc. announced the divestment of its FDA-approved drug, DSUVIA to Alora Pharmaceuticals (Alora).  The agreement allows AcelRx to participate in the long-term…
Read More...

Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) granted emergency use authorization (EUA) to provide a single booster dose of the companies’…
Read More...

Cingulate Inc., a biopharmaceutical company utilizing its proprietary Precision Timed Release (PTR) drug delivery platform technology to build and advance a pipeline of next-generation…
Read More...

Sanofi and Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D),…
Read More...

Pfizer Inc. and Seagen Inc. announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers,…
Read More...

Cytovance Biologics, Inc. (Cytovance Biologics), a biopharmaceutical contract development and manufacturing organization (CDMO), and Phenotypeca Limited (Phenotypeca), a research and…
Read More...

Cancer Research UK and UCB announced a clinical development collaboration to advance two of UCB’s investigational oncology antibody candidates through clinical trials. The…
Read More...

Sandoz signed a Memorandum of Understanding (MOU) to build a new biologics production plant in Lendava, Slovenia. The Sandoz investment is expected to be at least USD 400 million,…
Read More...

Alnylam Pharmaceuticals, Inc. and Medison Pharma have announced an expansion of their existing partnership to a multi-regional agreement that includes Poland, Czech Republic, Hungary,…
Read More...

Vertex Pharmaceuticals Incorporated announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-264, a stem…
Read More...

Tessa Therapeutics Ltd. (Tessa), a clinical-stage cell therapy company developing next-generation cancer treatments for hematological malignancies and solid tumors, announced entry into…
Read More...

OPKO Health, Inc. announced that ModeX Therapeutics, Inc., an OPKO Health company, entered into an exclusive worldwide license and collaboration agreement with Merck, known as MSD…
Read More...

Sun Pharmaceutical announced the successful completion of its acquisition of Concert Pharmaceuticals for the development of deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor,…
Read More...

Shorla Oncology (‘Shorla’) announced that the U.S. Food and Drug Administration (FDA) approved the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell Acute…
Read More...

The U.S. Food and Drug Administration (FDA) has accepted, for review, the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) to treat adults and adolescents aged…
Read More...

Eisai Co., Ltd. and Biogen Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted Eisai’s supplemental Biologics License Application (sBLA) for LEQEMBI™…
Read More...